Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document

Orphanet Journal of Rare Diseases

Volumn 10, Issue 1, 2015, Pages

  Biegstraaten, Marieke ^a   Arngrímsson, Reynir ^b   Barbey, Frederic ^c   Boks, Lut ^d   Cecchi, Franco ^e   Deegan, Patrick B ^f   Feldt Rasmussen, Ulla ^g   Geberhiwot, Tarekegn ^h   Germain, Dominique P ⁱ   Hendriksz, Chris ^j   Hughes, Derralynn A ^k   Kantola, Ilkka ^l   Karabul, Nesrin ^m   Lavery, Christine ^d   Linthorst, Gabor E ^a   Mehta, Atul ^k   Van De Mheen, Erica ⁿ   Oliveira, João P ^o   Parini, Rossella ^p   Ramaswami, Uma ^q   Rudnicki, Michael ^r   Serra, Andreas ^s   Sommer, Claudia ^t   Sunder Plassmann, Gere ^u   Svarstad, Einar ^v   Sweeb, Annelies ⁿ   Terryn, Wim ^w   Tylki Szymanska, Anna ^x   Tøndel, Camilla ^v   Vujkovac, Bojan ^y   Weidemann, Frank ^z   Wijburg, Frits A ^a   Woolfson, Peter ^aa   Hollak, Carla Em ^a   more..

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ICELAND   (Iceland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d Fabry International Network (FIN)   (United Kingdom)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g Mental Health Services CPH   (Denmark)

^h UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

ⁱ LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l TURKU UNIVERSITY HOSPITAL   (Finland)

^m Villa Metabolica   (Germany)

ⁿ Fabry Support and Information Group the Netherlands (FSIGN)   (Netherlands)

^o UNIVERSITY OF PORTO   (Portugal)

^p SAN GERARDO HOSPITAL   (Italy)

^q ROYAL FREE HOSPITAL   (United Kingdom)

^r INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^s UNIVERSITY OF ZURICH   (Switzerland)

^t UNIVERSITY OF WÜRZBURG   (Germany)

^u MEDICAL UNIVERSITY OF VIENNA   (Austria)

^v HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^w GHENT UNIVERSITY HOSPITAL   (Belgium)

^x CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^y General Hospital Slovenj Gradec   (Slovenia)

^z Katharinen Hospital Unna   (Germany)

^aa HOPE HOSPITAL   (United Kingdom)

more..

Author keywords

Delphi procedure; Enzyme replacement therapy; Fabry disease; Recommendations

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; ISOENZYME;

ADOLESCENT; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; COGNITIVE DEFECT; COMORBIDITY; CONSENSUS; CORNEA DISEASE; CORNEA VERTICILLATA; DELPHI STUDY; DIALYSIS; DISEASE SEVERITY; END STAGE RENAL DISEASE; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HEALTH SURVEY; HEART DISEASE; HEART FAILURE; HEMANGIOKERATOMA; HUMAN; KIDNEY DISEASE; LIFE EXPECTANCY; MALE; NEUROPATHIC PAIN; NEW YORK HEART ASSOCIATION CLASS; ONLINE SYSTEM; PATIENT COMPLIANCE; PHYSICAL DISEASE BY BODY FUNCTION; SEVERE RENAL IMPAIRMENT; TREATMENT INDICATION; TREATMENT RESPONSE; DISEASE COURSE; PATHOLOGY; PRACTICE GUIDELINE;

ADOLESCENT; ALPHA-GALACTOSIDASE; DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; ISOENZYMES; MALE; PRACTICE GUIDELINES AS TOPIC;

EID: 84961291260     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-015-0253-6     Document Type: Article

References (41)

1. Desnick RJ, Ioannou YA, Eng ME. α-Galactosidase A deficiency: Fabry disease, The online metabolic and molecular bases of inherited disease. 2007. p. 3733-74.
2. Meikle PJ, Hopwood JJ, Clague AE, Carey WF, et al. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249-54.
3. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105(1-2):151-6.
4. Van der Tol L, Smid BE, Poorthuis BJHM, Biegstraaten M, Lekanne Deprez RH, Linthorst GE, et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51(1):1-9.
5. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L, et al. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med. 1967;276(21):1163-7.
6. Kint JA. Fabry's disease: alpha-galactosidase deficiency. Science. 1970;167(3922):1268-9.
7. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38(11):750-60.
8. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38(11):769-75.
9. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, et al. Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138(4):338-46.
10. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One. 2007;2(7):e598.
11. Sirrs SM, Bichet DG, Casey R, Clarke JT, Lemoine K, Doucette S, et al. Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab. 2014;111(4):499-506.
12. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146(2):77-86.
13. Bierer G, Balfe D, Wilcox WR, Mosenifar Z, et al. Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. J Inherit Metab Dis. 2006;29(4):572-9.
14. Hughes DA, Elliot PM, Shah J, Zuckerman J, Coghlan G, Brookes J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008;94(2):153-8.
15. Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MG, Hollak CEM, et al. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis. 2014;37(3):341-52.
16. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002;62(6):1933-46.
17. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18:1547-57.
18. Tøndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013;24(1):137-48.
19. Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE, et al. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis. 2013;8:47.
20. Buechner S, Moretti M, Burlina A, Cei G, Manara R, Ricci R, et al. Central nervous system involvement in Anderson-Fabry disease: A clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry. 2008;79(11):1249-54.
21. Jardim L, Vedolin L, Schwartz IV, Burin MG, Cecchin C, Kalakun L, et al. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis. 2004;27(2):229-40.
22. Jardim LB, Aesse F, Vedolin L, Pitta-Pinheiro C, Marconato J, Burin MG, et al. White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up. Arq Neuropsiquiatr. 2006;64(3B):711-7.
23. Weidemann F, Niemann M, Störk S, Breunig F, Beer M, Sommer C, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013;274(4):331-41.
24. Smid BE, Van der Tol L, Cecchi F, Elliott PM, Hughes DA, Linthorst GE, et al. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol. 2014;177(2):400-8.
25. Schiffmann R, Kopp JB, Austin HAI, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743-9.
26. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med. 2001;345(1):9-16.
27. Ries M, Clarke JTR, Whybra C, Timmons M, Robinson C, Schlaggar BL, et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics. 2006;118:924-32.
28. Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr. 2007;96(1):122-7.
29. Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr. 2008;152(4):563-70.
30. Schiffmann R, Martin RA, Reimschisel T, Johnson K, Castaneda V, Lien YH, et al. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr. 2010;156(5):832-7.
31. Ramaswami U, Parini R, Kampmann C, Beck M, et al. Safety of agalsidase alfa in patients with Fabry disease under 7 years. Acta Paediatr. 2011;100(4):605-11.
32. Borgwardt L, Feldt-Rasmussen U, Rasmussen AK, Ballegaard M, Meldgaard Lund A, et al. Fabry disease in children: agalsidase-beta enzyme replacement therapy. Clin Genet. 2013;83(5):432-8.
33. Rombach SM, Aerts JM, Poorthuis BJ, Groener JE, Donker-Koopman W, Hendriks E, et al. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One. 2012;7(10):e47805.
34. Bénichou B, Goyal S, Sung C, Norfleet AM, O'Brien F, et al. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab. 2009;96(1):4-12.
35. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003.
36. Glassock RJ, Winearls C. Ageing and the Glomerular Filtration Rate: Truths and Consequences. Trans Am Clin Climatol Assoc. 2009;120:419-28.
37. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009;119(4):524-9.
38. KDIGO Clinical Practice Guidelines. http://kdigo.org/home/guidelines/.
39. ESC Clinical Practice Guidelines. http://www.escardio.org/guidelines.
40. AHA/ASA Guideline. https://www.aan.com/Guidelines/home/GetGuidelineContent/581.
41. Van der Tol L, Svarstad E, Ortiz A, Tøndel C, Oliveira JP, Vogt L, et al. Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis. Mol Genet Metab. 2015;114(2):242-7.